α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease

10.1002/mds.1090

10.1016/0166-2236(89)90074-X

10.1152/physrev.00015.2008

10.1111/j.1460-9568.1997.tb01702.x

10.1002/mds.20029

10.1002/mds.20117

10.1016/j.bcp.2009.06.024

10.1111/j.1471-4159.1988.tb02497.x

10.1111/j.1471-4159.1992.tb09752.x

10.1152/jn.90548.2008

10.1016/j.neuroscience.2006.11.011

10.1016/S0306-4522(03)00220-3

10.1002/cne.10138

10.1517/14656560903329102

10.1007/978-3-540-69248-5_7

10.1073/pnas.1009874107

10.1177/0891988710383572

10.1016/S0166-4328(00)00197-2

10.1016/S1474-4422(08)70291-6

10.1038/aps.2009.37

10.1016/S0014-2999(00)00807-4

Bencherif, 1996, RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization, J Pharmacol Exp Ther, 279, 1413

10.1056/NEJMra0809890

10.1111/j.1471-4159.1988.tb10600.x

10.1016/j.bcp.2007.07.011

10.1016/j.tins.2007.03.006

10.1016/j.expneurol.2004.10.004

10.1046/j.1469-7580.2000.19640527.x

10.1124/jpet.108.140897

10.1124/jpet.109.162396

10.1124/mol.107.035998

Braak, 2002, Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages), J Neurol, 249, III/1, 10.1007/s00415-002-1301-4

10.1016/S0197-4580(02)00065-9

Breese, 1997, Effect of smoking history on [3H]nicotine binding in human postmortem brain, J Pharmacol Exp Ther, 282, 7

10.1111/j.1460-9568.2005.04190.x

10.1124/jpet.108.145292

10.1016/j.tips.2005.05.007

10.1124/pr.108.000562

10.1016/S0166-2236(99)01501-5

10.1111/j.1469-7793.1998.421bk.x

10.1016/j.neuron.2008.09.031

10.1016/S1474-4422(10)70218-0

10.1523/JNEUROSCI.0252-10.2010

10.1093/brain/awm082

10.1016/j.parkreldis.2008.04.021

10.1016/S0079-6123(08)00922-9

10.1074/jbc.271.13.7522

10.1016/S0161-813X(03)00107-4

10.1021/tx000224v

10.1016/S0896-6273(04)00115-1

10.1016/S0079-6123(10)83011-0

Cenci MA Lundblad M (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9:Unit 9.25.

Champtiaux, 2003, Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice, J Neurosci, 23, 7820, 10.1523/JNEUROSCI.23-21-07820.2003

Champtiaux, 2002, Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice, J Neurosci, 22, 1208, 10.1523/JNEUROSCI.22-04-01208.2002

10.1146/annurev.pharmtox.010909.105741

10.1038/nrn2849

10.1212/WNL.0b013e3181d55f38

10.1074/jbc.M109.017384

10.1038/289537a0

10.1111/j.1460-9568.1993.tb00479.x

Clarke, 1985, Electrophysiological actions of nicotine on substantia nigra single units, Br J Pharmacol, 85, 827, 10.1111/j.1476-5381.1985.tb11081.x

10.1016/0306-4522(87)90176-X

10.1016/0006-8993(85)90456-1

10.1007/BF02245195

10.1021/jm050069n

10.1016/j.tips.2008.12.002

10.1146/annurev.pharmtox.40.1.431

10.1016/j.jphysparis.2005.12.012

10.1021/jm960328w

10.1016/S0006-8993(00)03087-0

10.1016/S0306-4522(00)00071-3

Cragg, 2003, Variable dopamine release probability and short-term plasticity between functional domains of the primate striatum, J Neurosci, 23, 4378, 10.1523/JNEUROSCI.23-10-04378.2003

10.1016/j.tins.2006.01.003

10.1097/ALN.0b013e3181834490

Cui, 2003, The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors, J Neurosci, 23, 11045, 10.1523/JNEUROSCI.23-35-11045.2003

10.1136/pgmj.53.626.719

10.1016/j.tips.2004.04.006

10.1016/S0014-2999(00)00003-0

10.1016/S0166-2236(02)02181-1

10.1016/S0301-0082(97)00050-6

10.1016/S0079-6123(08)00921-7

10.1006/exnr.1999.7106

Donnelly-Roberts, 1998, ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization, J Pharmacol Exp Ther, 285, 777

10.1016/0006-8993(96)00063-7

Dowell, 2003, Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors, J Neurosci, 23, 8445, 10.1523/JNEUROSCI.23-24-08445.2003

10.1523/JNEUROSCI.2056-10.2010

10.1016/j.neuron.2008.09.009

10.1212/01.wnl.0000310414.85144.ee

10.1002/ana.410280202

Dwoskin, 2009, Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse, Neuropsychopharmacology, 34, 244, 10.1038/npp.2008.157

10.1002/1531-8257(199911)14:6<1011::AID-MDS1016>3.0.CO;2-F

Elbaz, 2008, Update in the epidemiology of Parkinson's disease, Curr Opin Neurol, 21, 454, 10.1097/WCO.0b013e3283050461

10.1002/syn.20630

10.1016/j.pbb.2007.05.002

10.1038/sj.npp.1301617

10.1038/sj.bjp.0707510

10.1007/BF02244882

Fahn, 2008, How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?, Ann Neurol, 64, S56, 10.1002/ana.21453

10.2165/11533740-000000000-00000

10.1038/nn1103

10.1152/jn.00361.2002

10.1046/j.1460-9568.2003.02511.x

10.1038/379733a0

10.1073/pnas.93.24.14065

10.1016/S0079-6123(08)00923-0

10.1016/j.ceca.2003.08.006

10.1016/0168-0102(94)00869-H

10.1126/science.2147780

10.1002/mds.21894

10.1001/jama.296.1.47

10.1212/WNL.52.1.115

10.1016/j.neuropharm.2007.07.007

10.1523/JNEUROSCI.5095-09.2010

10.1016/j.nbd.2006.04.005

10.1124/mol.105.011940

10.1016/j.bcp.2007.05.023

10.2174/138161206775474486

10.1016/j.bcp.2009.06.011

10.1016/0306-4522(83)90135-5

10.1016/0306-4522(83)90136-7

10.1016/0306-4522(83)90137-9

Grace, 1984, The control of firing pattern in nigral dopamine neurons: burst firing, J Neurosci, 4, 2877, 10.1523/JNEUROSCI.04-11-02877.1984

Grace, 1984, The control of firing pattern in nigral dopamine neurons: single spike firing, J Neurosci, 4, 2866, 10.1523/JNEUROSCI.04-11-02866.1984

10.1016/j.tins.2007.03.003

Grace, 1989, Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro, J Neurosci, 9, 3463, 10.1523/JNEUROSCI.09-10-03463.1989

10.1016/j.neuropharm.2010.01.013

10.1016/j.bcp.2007.07.032

10.1007/s12031-009-9263-y

Graybiel, 1990, Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradients and compartments, J Neurosci, 10, 720, 10.1523/JNEUROSCI.10-03-00720.1990

10.1111/j.1748-1716.1986.tb07988.x

10.1016/j.neuropharm.2008.10.014

Haber, 1986, Neurotransmitters in the human and nonhuman primate basal ganglia, Hum Neurobiol, 5, 159

10.1124/jpet.105.090852

10.1111/j.1471-4159.2004.02574.x

10.1046/j.1460-9568.2000.00262.x

10.1002/mds.21177

10.1002/jnr.21293

10.1002/mds.22242

10.1002/ana.10028

Hill, 1993, Immunocytochemical localization of a neuronal nicotinic receptor: the beta 2-subunit, J Neurosci, 13, 1551, 10.1523/JNEUROSCI.13-04-01551.1993

10.1016/j.neuropharm.2010.12.032

10.1111/j.1471-4159.2009.06011.x

10.1016/0022-510X(93)90150-W

10.2165/00023210-200721080-00005

10.1002/ana.21587

10.1038/nrn2471

10.1016/j.tips.2010.07.001

10.1002/cne.1345

10.1001/jama.296.1.56

10.1124/mol.58.2.312

10.1152/jn.00760.2007

Kelton, 2000, The effects of nicotine on Parkinson's disease, Brain Cogn, 43, 274

10.1016/S0959-4388(99)00040-9

Klink, 2001, Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei, J Neurosci, 21, 1452, 10.1523/JNEUROSCI.21-05-01452.2001

Koós, 2002, Dual cholinergic control of fast-spiking interneurons in the neostriatum, J Neurosci, 22, 529, 10.1523/JNEUROSCI.22-02-00529.2002

10.1016/j.neuron.2008.11.005

10.1124/mol.61.1.230

10.1046/j.1471-4159.2001.00357.x

Kulak, 1997, Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes, J Neurosci, 17, 5263, 10.1523/JNEUROSCI.17-14-05263.1997

10.1046/j.1471-4159.2002.00868.x

10.1124/mol.108.046789

Lacey, 1989, Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids, J Neurosci, 9, 1233, 10.1523/JNEUROSCI.09-04-01233.1989

10.1124/mol.104.006429

10.1212/WNL.0b013e318198e177

10.1016/j.pharmthera.2007.09.009

10.1002/cne.903440204

10.1111/j.1460-9568.1996.tb01206.x

10.1016/j.nbd.2009.12.027

Lee, 2009, Basal ganglia control of substantia nigra dopaminergic neurons, J Neural Transm Suppl, 73, 71

10.1016/S0278-5846(03)00172-6

10.1016/0166-2236(93)90150-K

10.1208/s12248-009-9090-7

10.1097/00008877-199911000-00014

10.1016/0028-3908(82)90107-1

10.1385/JMN:30:1:19

10.1016/j.bcp.2009.06.004

10.1016/S0306-4522(98)00748-9

10.1016/0014-5793(88)81454-6

10.1016/j.neuron.2006.05.007

10.1016/S0896-6273(00)00042-8

10.1007/s12031-009-9230-7

10.1046/j.0022-3042.2002.00805.x

Marks, 1983, Effects of chronic nicotine infusion on tolerance development and nicotinic receptors, J Pharmacol Exp Ther, 226, 817

Marks, 1992, Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment, J Neurosci, 12, 2765, 10.1523/JNEUROSCI.12-07-02765.1992

Marks, 1986, Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin, Mol Pharmacol, 30, 427

10.1016/j.bcp.2009.05.022

10.1046/j.1471-4159.1997.68041511.x

10.1007/s00213-003-1750-1

10.1038/bjp.2008.5

10.1111/j.1471-4159.2010.06798.x

10.1007/s00213-006-0441-0

10.1146/annurev.neuro.26.043002.094919

10.1111/j.1471-4159.2005.03646.x

10.1124/mol.108.052274

10.1016/j.bcp.2009.05.020

10.1124/mol.65.4.944

10.1146/annurev.biochem.68.1.59

10.1016/j.bcp.2007.07.001

10.1016/j.brainresrev.2008.02.003

10.1006/exnr.2002.7900

10.1111/j.1471-4159.2008.05266.x

10.1124/mol.106.025130

Miksys S Tyndale RF (2006) Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl (70):177–180.

10.1038/sj.bjp.0707661

10.1016/j.neuropharm.2008.07.041

10.1016/j.tips.2010.09.004

10.1007/s00441-004-0918-2

Mitsuoka, 2002, Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism, Hiroshima J Med Sci, 51, 33

10.1124/jpet.302.1.197

Morens, 1995, Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?, Neurology, 45, 1041, 10.1212/WNL.45.6.1041

10.1124/mol.110.064071

10.1016/j.neuropharm.2009.12.024

10.1124/mol.106.023044

10.1002/mds.22045

10.1016/j.neuroscience.2005.09.008

10.1124/mol.57.3.642

10.1016/0896-6273(92)90115-T

10.1093/brain/awn235

10.1124/mol.63.2.332

10.1124/jpet.103.056408

10.1515/REVNEURO.1993.4.2.213

10.2174/1568007023339166

10.1002/mds.20587

10.1002/mds.21813

10.1016/S1471-1931(00)00031-8

10.1038/nm.2165

10.1146/annurev.med.55.091902.104422

10.1016/S0165-0173(97)00039-8

10.1038/sj.bjp.0704833

10.1016/0166-2236(90)90105-J

10.1016/S1471-1931(00)00022-7

10.1124/mol.65.3.611

10.1212/01.wnl.0000196466.99381.5c

Pauly, 1991, An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment, J Pharmacol Exp Ther, 258, 1127

10.1124/mol.108.048843

10.1124/mol.108.053801

Perry, 1999, Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies, J Pharmacol Exp Ther, 289, 1545

10.1124/jpet.107.121228

10.1016/0306-4522(94)00410-7

10.1517/14656561003598919

10.1007/s00213-010-1932-6

10.1016/j.pneurobio.2007.12.005

10.2741/2695

10.1038/nn1040

10.1016/j.bcp.2009.05.014

10.1212/WNL.0b013e31819908ce

10.1113/jphysiol.2007.149963

10.1016/j.bcp.2009.04.031

Pucak, 1994, Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors, J Pharmacol Exp Ther, 271, 1181

10.1016/S0006-8993(02)03340-1

10.1007/s00213-008-1281-x

10.1111/j.1471-4159.2004.02177.x

10.1007/s12031-009-9265-9

10.1523/JNEUROSCI.0215-06.2006

10.1002/ana.21203

10.1016/j.bcp.2009.05.003

10.1124/jpet.105.094375

10.1016/j.tips.2007.03.001

10.1111/j.1471-4159.2006.04078.x

10.1002/1096-9861(20000911)425:1<58::AID-CNE6>3.0.CO;2-X

10.1016/S0306-4522(00)00244-X

Quik, 2001, Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey, J Neurosci, 21, 5494, 10.1523/JNEUROSCI.21-15-05494.2001

10.1016/S0306-4522(02)00106-9

10.1124/mol.63.5.1169

10.1124/mol.104.006015

10.1023/B:NERE.0000035803.64724.17

10.1016/j.neuroscience.2004.08.010

10.1016/0006-8993(90)90520-L

10.1016/S0028-3908(99)00147-1

10.1007/s12031-009-9272-x

10.1038/nn1244

10.1212/WNL.0b013e3181d63aa8

10.1001/archneur.64.7.990

10.1016/0166-2236(92)90034-6

10.1016/j.neuropharm.2006.10.016

10.1016/j.tips.2007.05.003

10.1038/sj.bjp.0703989

10.1016/j.nbd.2010.05.001

10.1016/j.neuron.2005.03.029

10.1124/mol.106.031492

10.1124/mol.65.6.1526

10.1016/S0140-6736(04)16305-8

10.1016/0006-8993(91)90810-I

10.1523/JNEUROSCI.0852-07.2007

10.1016/j.bcp.2009.04.019

10.1016/j.tips.2008.10.005

10.1111/j.1468-1331.2009.02697.x

10.1017/S1461145702003188

10.1002/mds.870130405

10.1126/science.6828889

10.1111/j.1471-4159.1984.tb02818.x

Séguéla, 1993, Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium, J Neurosci, 13, 596, 10.1523/JNEUROSCI.13-02-00596.1993

10.1111/j.1471-4159.2010.06883.x

Sharples, 2000, UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes, J Neurosci, 20, 2783, 10.1523/JNEUROSCI.20-08-02783.2000

10.2174/1568007024606168

10.1016/0166-2236(90)90106-K

10.1016/S1471-1931(00)00023-9

10.1016/j.neulet.2010.10.049

Soliakov, 1996, Voltage-sensitive Ca2+ channels involved in nicotinic receptor-mediated [3H]dopamine release from rat striatal synaptosomes, J Neurochem, 67, 163, 10.1046/j.1471-4159.1996.67010163.x

10.1016/S0006-2952(02)01070-5

10.1523/JNEUROSCI.0546-06.2006

Sullivan, 1997, ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties, J Pharmacol Exp Ther, 283, 235

10.1016/0896-6273(95)90294-5

10.1146/annurev.pharmtox.44.101802.121415

10.1016/S1040-7952(99)80005-6

10.1016/j.conb.2004.10.003

10.1212/01.wnl.0000256374.50227.4b

10.1007/BF00966669

10.1111/j.1750-3639.2009.00296.x

10.1046/j.1460-9568.2000.00138.x

10.1124/mol.106.027326

10.1016/j.neuron.2006.05.024

10.1016/S0014-5793(03)01084-6

10.1073/pnas.0408305102

Vieregge, 2001, Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study, Neurology, 57, 1032, 10.1212/WNL.57.6.1032

10.1111/j.1468-1331.2007.01949.x

10.1002/cne.902840212

10.1074/jbc.M703432200

10.1074/jbc.M705369200

10.1002/cne.10086

10.1111/j.1460-9568.2008.06576.x

10.1038/sj.bjp.0706621

10.1016/0014-5793(90)81231-C

Whiteaker, 2000, 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain, Mol Pharmacol, 57, 913

Whiteaker, 2002, Involvement of the alpha3 subunit in central nicotinic binding populations, J Neurosci, 22, 2522, 10.1523/JNEUROSCI.22-07-02522.2002

10.1007/s00018-006-6081-z

Wilson, 1990, Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum, J Neurosci, 10, 508, 10.1523/JNEUROSCI.10-02-00508.1990

10.1002/cne.901940308

10.1046/j.1460-9568.2003.02492.x

10.1371/journal.pone.0010396

10.1016/S0166-2236(96)10073-4

Wooltorton, 2003, Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas, J Neurosci, 23, 3176, 10.1523/JNEUROSCI.23-08-03176.2003

10.1523/JNEUROSCI.2939-09.2009

10.1124/mol.106.027318

10.1038/4516

10.1016/S0361-9230(00)00237-9

Yu, 1994, Chronic nicotine administration differentially affects neurotransmitter release from rat striatal slices, J Neurochem, 63, 186, 10.1046/j.1471-4159.1994.63010186.x

Zhang, 2003, Glutamate spillover in the striatum depresses dopaminergic transmission by activating group I metabotropic glutamate receptors, J Neurosci, 23, 10585, 10.1523/JNEUROSCI.23-33-10585.2003

10.1038/nn1243

10.1124/mol.109.056317

10.1523/JNEUROSCI.0261-09.2009

10.1016/j.mcn.2008.11.001

10.1038/nn769

10.1002/neu.10150

10.1523/JNEUROSCI.4402-08.2009

10.1016/j.biopsych.2005.05.026

Zoli, 2002, Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum, J Neurosci, 22, 8785, 10.1523/JNEUROSCI.22-20-08785.2002

10.1124/mol.108.045104